2019

/Tag:2019

Oramed to Present at World Diabetes Congress

NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will deliver two presentations at the World Diabetes [...]

2019-07-10T08:40:00+00:00 Categories: Press Releases|Tags: |

Oramed Announces Xiaoming Gao Joins Board of Directors

Chairman of HTIT has decades of experience in the diabetes sector in China NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining [...]

2019-07-02T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at BIO International Convention

NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business Development of Oramed, will deliver a corporate presentation, including an [...]

2019-06-03T09:25:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at ThinkEquity Conference

NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. [...]

2019-04-29T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at 3rd Annual Clinical Trials Summit

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]

2019-04-11T08:55:00+00:00 Categories: Press Releases|Tags: |

Oramed Patent Allowed in the U.S. for Oral Exenatide

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]

2019-04-04T08:55:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present at H.C. Wainwright Global Life Sciences Conference

NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place [...]

2019-04-03T08:55:00+00:00 Categories: Press Releases|Tags: |

Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for [...]

2019-03-28T08:40:00+00:00 Categories: Press Releases|Tags: |